Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(13 sites)
United States
Valkyrie Clinical Trials, Los Angeles, California Indiana University, Indianapolis, Indiana The University of Texas MD Anderson Cancer Center, Houston, Texas Belgium
Cliniques Universitaires Saint-Luc, Brussels France
INS Paoli-Calmettes, Marseille Institut Gustave Roussy, Villejuif Germany
Klinikum der Universität München AÖR, München Universitätsklinikum Würzburg AÖR, Würzburg Japan
National Cancer Center Hospital East, Chiba, Kashiwa Japanese Foundation for Cancer Research, Tokyo, Koto-ku Spain
Hospital Universitari Vall d'Hebron, Barcelona Clínica Universidad de Navarra - Madrid, Madrid